Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$1,386.23

46.63 (3.48%)

, WBA

Walgreens Boots Alliance

$68.46

(0.00%)

10:46
02/13/18
02/13
10:46
02/13/18
10:46

Medical suppliers slide as Amazon looms, Walgreens pursues AmerisourceBergen

Two news reports are moving several names in the medical supply space this morning. Namely, Amazon (AMZN) is said to be looking to expand its medical supplies business, while Walgreens Boots Alliance (WBA) has approached AmerisourceBergen (ABC) about a potential takeover. Shares of Owens & Minor (OMI), McKesson (MCK), and Cardinal Health (CAH) are all slipping following the two Wall Street Journal scoops. AMAZON RAMPS UP IN MEDICAL SUPPLY: Amazon is seeking to expand its medical supplies business into being a major distributor to hospitals and outpatient clinics, according to The Wall Street Journal. The e-commerce giant is currently running a pilot with a Midwestern hospital system to supply its 150 outpatient facilities, the publication said. Typically, hospitals sign contracts to buy supplies directly from manufacturers or distributors like Owens & Minor, McKesson, Cardinal Health and Medline Industries. WALGREENS DEAL INTEREST: Meanwhile, The Wall Street Journal separately reported, citing sources, that Walgreens reached out several weeks ago to Amerisource to discuss the possibility of buying the portion of the company it doesn't already own. The sources added, though, that there is not an offer on the table. In a research note to investors, Jefferies analyst Brian Tanquilut pointed out that while Walgreens acquiring AmerisourceBergen would be EPS-accretive and would allow the former to take advantage of its strong free cash flow and balance sheet, the rationale for such a deal is a bit of a "headscratcher" as both companies already have a joint venture that affords them the strategic value that combining would provide. Leerink analyst David Larsen told investors in a note of his own that he is surprised that talks of such a large transaction have surfaced so quickly following the Rite Aid (RAD) deal being blocked, but says he has always believed that Walgreens at some point would seek to acquire either Express Scripts (ESRX) or AmerisourceBergen. His peer at Loop Capital added that a full merger would have similar attributes to that of the vertically integrated pharmacy model that Walgreens operates in the U.K., which lowers product costs and working capital requirements to the benefit of all customers. Ultimately, analyst Andrew Wolf views this strategic response positively as it would better position a combined company to navigate in the face of industry change and possibly even be a disrupter, he said. Wells Fargo analyst Peter Costa also commented on The Journal report, saying he believes the acquisition makes sense given the already existing long-term partnership and limited ability to merge laterally. Further, the analyst argued that a potential combination could help lower costs and wring out synergies in the U.S. drug distribution channel, and better position Walgreens in the face of increasing competitive threat from a possible Amazon entry. However, a merger might risk alienating AmerisourceBergen's retail pharmacy customers that compete with Walgreens' pharmacies, he contended. PRICE ACTION: In morning trading, shares of Amazon have gained over 2% to $1,415, while Walgreens is fractionally higher and AmerisourceBergen shares have jumped 8%. Moving in the opposite direction, Owens & Minor is sliding 8%, McKesson is slipping 2% and Cardinal Health is down 4%.

AMZN

Amazon.com

$1,386.23

46.63 (3.48%)

WBA

Walgreens Boots Alliance

$68.46

(0.00%)

ABC

AmerisourceBergen

$97.35

7.9 (8.83%)

OMI

Owens & Minor

$14.59

-1.11 (-7.07%)

MCK

McKesson

$145.89

-3.13 (-2.10%)

CAH

Cardinal Health

$65.37

-2.66 (-3.91%)

ESRX

Express Scripts

$72.89

1.18 (1.65%)

RAD

Rite Aid

$2.04

0.039 (1.95%)

  • 14

    Feb

  • 16

    Feb

  • 17

    Feb

  • 21

    Feb

  • 28

    Feb

  • 18

    Mar

AMZN Amazon.com
$1,386.23

46.63 (3.48%)

02/13/18
DADA
02/13/18
NO CHANGE
Target $1800
DADA
Buy
Amazon.com investors should take advantage of pullback, says DA Davidson
DA Davidson analyst Tom Forte keeps his Buy rating and $1,800 on Amazon.com but says that investors should take advantage of the latest pullback to add to their positions. In addition to valuation, Forte cites the press reports on the latest hiring of Jennifer Salke as the new head of Amazon Studios, thereby filling "an important void after a potential period of disruption" and bringing one of its most significant areas of investment - proprietary content - back on track. The analyst notes that among Salke's prior accomplishments as the President of NBC Entertainment were hit shows such as "This Is Us", "Glee", "Modern Family", and "Prison Break".
02/13/18
WELS
02/13/18
NO CHANGE
WELS
AmerisourceBergen acquisition by Walgreens makes sense, says Wells Fargo
Commenting on The Wall Street Journal report saying Walgreens (WBA) has approached AmerisourceBergen (ABC) in a takeover attempt and the companies remain early in their discussions, Wells Fargo analyst Peter Costa tells investors he believes the acquisition makes sense given the already existing long-term partnership and limited ability to merge laterally. Further, the analyst believes a potential combination could help lower costs and wring out synergies in the U.S. drug distribution channel, and better position Walgreens in the face of increasing competitive threat from a possible Amazon (AMZN) entry. However, a merger might risk alienating AmerisourceBergen's retail pharmacy customers that compete with Walgreens' pharmacies, he contends.
02/13/18
MACQ
02/13/18
NO CHANGE
Target $1750
MACQ
Outperform
Amazon's Twitch aggregate viewership continues to rise, says Macquarie
Macquarie analyst Benjamin Schachter says Amazon's (AMZN) Twitch aggregate viewership continues to rise, and Twitch is now bigger than CNN (TWX). While eSports as a whole is becoming a more concrete opportunity, the analyst notes that which games and genres will be the most popular/viewed eSports over time is unclear. Schachter also highlights that the Overwatch League launched to peak views of over 408K and over 10M unique viewers across the opening week, and that display ads on Amazon properties like Twitch are meaningful contributors to Other revenue, which grew 58% to $4.65B in 2017. He reiterates an Outperform rating and $1,750 price target on Amazon's shares.
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
WBA Walgreens Boots Alliance
$68.46

(0.00%)

02/13/18
JEFF
02/13/18
NO CHANGE
Target $93
JEFF
Buy
Walgreens deal for AmerisourceBergen would be 'headscratcher,' says Jefferies
Jefferies analyst Brian Tanquilut says that while Walgreens Boots Alliance (WBA) acquiring AmerisourceBergen (ABC) would be accretive to earnings, it would be a "headscratcher" for investors. The companies already have a joint venture that affords both the strategic value that combining would provide, Tanquilut tells investors in a research note after the Wall Street Journal reported that Walgreens approached AmerisourceBergen a few weeks ago. The analyst has a Buy rating on Walgreens with a $93 price target. He adds that the potential deal would allow Walgreens to further expand its U.S. business.
02/13/18
LEER
02/13/18
NO CHANGE
LEER
Walgreens may seek to acquire AmerisourceBergen sooner than expected, says Leerink
Leerink analyst David Larsen notes that The Wall Street Journal reported that Walgreens (WBA) has approached AmerisourceBergen (ABC) about a potential takeover. The analyst is surprised that talks of such a large transaction have surfaced so quickly following the Rite Aid (RAD) deal, but says he has always believed that Walgreens at some point would seek to acquire either Express Scripts (ESRX) or AmerisourceBergen. Given the broad-based speculation in the business press about this deal, it is possible shares of Express Scripts will trade off, Larsen contends.
02/13/18
LOOP
02/13/18
NO CHANGE
Target $90
LOOP
Buy
AmerisourceBergen acquisition by Walgreens would model U.K., says Loop Capital
Loop Capital analyst Andrew Wolf believes that a Walgreens (WBA) and AmerisourceBergen (ABC) full merger would have similar attributes to that of the vertically integrated pharmacy model that Walgreens operates in the U.K. If completed, this transaction would come sooner than the analyst would have anticipated likely spurred by the rapid changes in pharmacy and healthcare occurring around Walgreens. Ultimately, Wolf views this strategic response positively as it would better position a combined company to navigate in the face of industry change and possibly even as a disrupter. He reiterates a Buy rating and $90 price target on Walgreens' shares.
ABC AmerisourceBergen
$97.35

7.9 (8.83%)

OMI Owens & Minor
$14.59

-1.11 (-7.07%)

12/19/17
JPMS
12/19/17
DOWNGRADE
Target $22
JPMS
Underweight
Owens & Minor downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Lisa Gill downgraded Owens & Minor to Underweight and cut her price target for the shares to $22 from $28. The analyst sees integration risk from the Halyard Health S&IP business acquisition and believes the Q3 miss presents concerns around management's 1%-3% organic top-line growth targets.
12/04/17
LEER
12/04/17
NO CHANGE
LEER
Amazon entry into healthcare markets focused on medical supplies, says Leerink
Leerink analyst David Larsen says that his recent research around Amazon's (AMZN) licensing activity has shown that the company's entry into healthcare markets is, at least for now, focused on medical supplies and devices rather than pharmaceuticals. The analyst believes Owens & Minor (OMI), Cardinal Health (CAH) and Henry Schein (HSIC) are most exposed but that it will take several years for Amazon Business to scale up manufacturer supply relationships to take significant share. Although the top and bottom line impact may be small over the next year or two, Larsen remains cautious on the group as multiples continue to reflect the Amazon threat as well as pricing and volume headwinds.
11/20/17
FBCO
11/20/17
NO CHANGE
Target $17
FBCO
Underperform
Owens & Minor price target lowered to $17 from $31 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for Owens & Minor to $17 from $31 following a "disappointing" Q3 performance, which highlighted likely continued headwinds near-term. The analyst reiterates an Underperform rating on the shares.
11/02/17
LEER
11/02/17
NO CHANGE
Target $23
LEER
Market Perform
Owens & Minor price target lowered to $23 from $34 at Leerink
Leerink analyst David Larsen lowered his price target for Owens & Minor to $23 from $34 saying that its core Domestic business continues to face pricing and margin pressures and growth in existing clients was behind expectations. The analyst reiterates a Market Perform rating on the shares.
MCK McKesson
$145.89

-3.13 (-2.10%)

01/23/18
NEED
01/23/18
NO CHANGE
Target $180
NEED
Buy
McKesson price target raised to $180 from $173 at Needham
Needham analyst Kevin Caliendo raised his price target on McKesson to $180 and kept his Buy rating ahead of the company's Q3 earnings next week. The analyst expects McKesson to update on the impact of U.S. corporate tax changes on earnings, anticipating it to be a net positive with a forward rate below the currently projected 24% in FY18.
01/24/18
JEFF
01/24/18
UPGRADE
Target $205
JEFF
Buy
McKesson upgraded to Buy from Hold at Jefferies
Jefferies analyst Brian Tanquilut upgraded McKesson to Buy and raised his price target for the shares to $205 from $165. The combination of stabilizing generic drug pricing, a discounted valuation relative to peers and higher earnings estimates due to tax reform will "boost investor interest this year and push the stock's multiple to more appropriate levels," Tanquilut tells investors in a research note. He sees 20% upside from current share levels.
01/24/18
01/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McKesson (MCK) upgraded to Buy from Hold at Jefferies analyst Brian Tanquilut saying the combination of stabilizing generic drug pricing, a discounted valuation relative to peers and higher earnings estimates due to tax reform will "boost investor interest this year and push the stock's multiple to more appropriate levels." 2. Cree (CREE) upgraded to Hold from Sell at Williams Capital. 3. 3M (MMM) upgraded to Buy from Neutral at Hilliard Lyons with analyst Spencer Joyce saying he sees as a tactical opportunity ahead of its earnings report as he expects estimates to rise following the company's fourth quarter earnings release. 4. Energen (EGN) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Evan Calio saying he expects oil markets to tighten and gas to remain weak in 2018. 5. Capital City Bank (CCBG) was upgraded to Outperform from Market Perform at Hovde Group and to Hold from Sell at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
COWN
02/12/18
NO CHANGE
COWN
Recent pullback in drug distributors a buying opportunity, says Cowen
Cowen analyst Charles Ryhee said the recent pullback in drug distributors is unwarranted given the space's improving underlying fundamentals. He said the core distribution business is seeing stable generic pricing for both buy-side and sell-side and he believes concerns regarding likely proposed Medicare Part B changes are overblown. Ryhee reiterated his Outperform rating on both McKesson (MCK) and AmerisourceBergen (ABC) shares.
CAH Cardinal Health
$65.37

-2.66 (-3.91%)

11/30/17
JEFF
11/30/17
NO CHANGE
JEFF
Jefferies sees drugstore sentiment improving with no Amazon news
Investors were anticipating an announcement from Amazon.com (AMZN) regarding a pharmacy strategy around Thanksgiving due to recent media reports and the resulting sell-side speculation, Jefferies analyst Brian Tanquilut tells investors in a research note. With no Amazon pharmacy entry announced one week removed from the holiday, the analyst believes investor sentiment over the drug supply chain may gradually improve, at least in the near-term. He notes that the price-to-earnings multiples of Walgreens Boots Alliance (WBA) and CVS Health (CVS) have already declined amid speculation of an Amazon entry. Tanquilut acknowledges, however, that the Amazon overhang will not completely go away. The analyst has Buy ratings on UnitedHealth (UNH) and Walgreens, and Hold ratings on AmerisourceBergen (ABC), Cardinal Health (CAH), CVS and McKesson (MCK).
12/04/17
DBAB
12/04/17
INITIATION
Target $64
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Cardinal Health with a Hold rating and $64 price target. The analyst believes uncertainty around drug pricing and the potential for integration risk with Cordis and the Patient Recovery acquisitions warrant a "more prudent approach" to the shares.
01/04/18
EVER
01/04/18
INITIATION
Target $67
EVER
In Line
Cardinal Health initiated with an In Line at Evercore ISI
Evercore ISI started Cardinal Health with an In Line rating and $67 price target.
ESRX Express Scripts
$72.89

1.18 (1.65%)

01/31/18
RBCM
01/31/18
UPGRADE
Target $98
RBCM
Outperform
Express Scripts upgraded to Outperform at RBC Capital
As reported earlier, RBC Capital analyst George Hill upgraded Express Scripts (ESRX) to Outperform and raised his price target to $98 from $68. Hill cites the "recent sharp pullback on Amazon's (AMZN) healthcare entry" de-risking the stock, while also pointing to the trend of vertical integration as seen in the CVS (CVS)-Aetna (AET) deal. The analyst believes Express Scripts could also become an attractive M&A target as "one of the few remaining assets at scale".
01/31/18
BERN
01/31/18
DOWNGRADE
BERN
Underperform
Express Scripts downgraded to Underperform from Market Perform at Bernstein
02/01/18
02/01/18
DOWNGRADE
Target $69

Underperform
Express Scripts downgraded to Underperform at Bernstein
As previously reported, Bernstein analyst Lance Wilkes downgraded Express Scripts to Underperform from Market Perform, with a $69 price target, as he believes tax reform is fully price in and his original concerns on the standalone PBM model remain. Further, the analyst sees additional risks from a potential CVS (CVS)/Aetna (AET) merger and Amazon (AMZN) threats.
RAD Rite Aid
$2.04

0.039 (1.95%)

01/02/18
LEER
01/02/18
NO CHANGE
Target $105
LEER
Outperform
AmerisourceBergen price target raised to $105 from $90 at Leerink
Leerink analyst David Larsen raised his price target for AmerisourceBergen (ABC) to $105 from $90, citing the H.D. Smith transaction and a more positive outlook for 2018 and 2019. The analyst notes that the company has completed its major renewals, generic deflation is stabilizing, and it will benefit from Prime, Rite Aid (RAD) and Walgreens Boots Alliance (WBA) volumes in 2018. He reiterates an Outperform rating on the shares.
01/04/18
EVER
01/04/18
INITIATION
Target $1.5
EVER
Underperform
Rite Aid initiated with an Underperform at Evercore ISI
Evercore ISI started Rite Aid with an Underperform rating and $1.50 price target.
01/04/18
COWN
01/04/18
NO CHANGE
Target $3
COWN
Outperform
Rite Aid Q3 results better than expected, says Cowen
Cowen analyst Charles Rhyee said Rite Aid's Q3 results were better than expected and he believes its Envison Rx will stabilize in 2019. He also noted management commentary was positive and suggested upside potential due to early relief in generic pricing beginning in 2019. Ryhee reiterated his Outperform rating and raised his price target to $2.50 from $2.15 on Rite Aid shares.

TODAY'S FREE FLY STORIES

IO

ION Geophysical

$21.40

0.05 (0.23%)

, SLB

Schlumberger

$67.25

2.46 (3.80%)

11:12
06/22/18
06/22
11:12
06/22/18
11:12
Hot Stocks
ION Geophysical says 'disappointed' with Supreme Court's ruling »

ION Geophysical…

IO

ION Geophysical

$21.40

0.05 (0.23%)

SLB

Schlumberger

$67.25

2.46 (3.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 20

    Jul

LMCA

Liberty Media

$0.00

(0.00%)

, LSXMA

Liberty SiriusXM

$46.08

0.41 (0.90%)

11:12
06/22/18
06/22
11:12
06/22/18
11:12
Hot Stocks
Liberty says withdrew iHeart proposal after reviewing results »

Liberty Media Corporation…

LMCA

Liberty Media

$0.00

(0.00%)

LSXMA

Liberty SiriusXM

$46.08

0.41 (0.90%)

IHRT

iHeartMedia

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$16.99

0.035 (0.21%)

11:10
06/22/18
06/22
11:10
06/22/18
11:10
Options
Arconic attracts a bullish option play as shares sit near 52-week lows »

Arconic attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$0.00

(0.00%)

11:09
06/22/18
06/22
11:09
06/22/18
11:09
Syndicate
Breaking Syndicate news story on Autolus Therapeutics »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CAR

Avis Budget

$42.45

1.2 (2.91%)

11:05
06/22/18
06/22
11:05
06/22/18
11:05
Options
Avis Budget call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$0.00

(0.00%)

10:56
06/22/18
06/22
10:56
06/22/18
10:56
Syndicate
Breaking Syndicate news story on Autolus Therapeutics »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

10:55
06/22/18
06/22
10:55
06/22/18
10:55
General news
U.S. equities rolled over with yields after Trump tweeted »

U.S. equities rolled over…

10:55
06/22/18
06/22
10:55
06/22/18
10:55
Conference/Events
The FDA Blood Products Advisory Committee to hold a meeting »

The Committee hears…

IO

ION Geophysical

$20.65

-0.7 (-3.28%)

, SLB

Schlumberger

$67.40

2.61 (4.03%)

10:52
06/22/18
06/22
10:52
06/22/18
10:52
Periodicals
Supreme Court backs Schlumberger in patent fight with ION, Reuters reports »

The U.S. Supreme Court…

IO

ION Geophysical

$20.65

-0.7 (-3.28%)

SLB

Schlumberger

$67.40

2.61 (4.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 20

    Jul

FNSR

Finisar

$17.03

-0.685 (-3.87%)

10:50
06/22/18
06/22
10:50
06/22/18
10:50
Options
Bearish option flow in Finisar as shares see relative weakness »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AUTL

Autolus Therapeutics

$0.00

(0.00%)

10:49
06/22/18
06/22
10:49
06/22/18
10:49
Syndicate
Autolus Therapeutics indicated to open at $30, IPO priced at $17.00 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

10:47
06/22/18
06/22
10:47
06/22/18
10:47
Conference/Events
Wells Fargo analysts to hold an analyst/industry conference call »

Analysts provide a 3Q18…

NUVA

NuVasive

$55.81

0.33 (0.59%)

10:45
06/22/18
06/22
10:45
06/22/18
10:45
Conference/Events
NuVasive has a conference call hosted by JPMorgan »

JPMorgan Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

HAIN

Hain Celestial

$30.23

1.04 (3.56%)

10:40
06/22/18
06/22
10:40
06/22/18
10:40
Options
5K Hain Celestial Aug 29 - 31 call spreads sold at 85c »

5K Hain Celestial Aug 29…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APO

Apollo Global

$31.89

0.18 (0.57%)

, HCP

HCP

$24.78

0.15 (0.61%)

10:37
06/22/18
06/22
10:37
06/22/18
10:37
Periodicals
Apollo the buyer of HCP senior housing portfolio, Bloomberg reports »

HCP (HCP) on June 5 said…

APO

Apollo Global

$31.89

0.18 (0.57%)

HCP

HCP

$24.78

0.15 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$472.84

9.97 (2.15%)

10:35
06/22/18
06/22
10:35
06/22/18
10:35
Options
Expiring Chipotle calls en fuego as shares head toward $500 »

Expiring Chipotle calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 26

    Jul

PAGS

PagSeguro Digital

$30.52

1.1 (3.74%)

10:30
06/22/18
06/22
10:30
06/22/18
10:30
Options
Three-way spreads continue in PagSeguro »

Three-way spreads…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

GM

General Motors

$41.70

0.575 (1.40%)

, F

Ford

$11.82

0.115 (0.98%)

10:28
06/22/18
06/22
10:28
06/22/18
10:28
General news
Trump says 20% tariffs may be placed on all imported European cars »

President Trump just…

GM

General Motors

$41.70

0.575 (1.40%)

F

Ford

$11.82

0.115 (0.98%)

HMC

Honda

$30.76

0.1 (0.33%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$131.64

-1 (-0.75%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$19.48

0.315 (1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

10:25
06/22/18
06/22
10:25
06/22/18
10:25
Conference/Events
Stephens food/agribusiness analyst to hold an analyst/industry conference call »

Food & Agribusiness…

QGEN

Qiagen

$36.61

0.41 (1.13%)

10:25
06/22/18
06/22
10:25
06/22/18
10:25
Conference/Events
Qiagen participates in a conference call with William Blair »

CFO Sachers participates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CMC

Commercial Metals

$23.22

0.96 (4.31%)

10:22
06/22/18
06/22
10:22
06/22/18
10:22
Recommendations
Commercial Metals analyst commentary  »

Commercial Metals to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STG

Sunlands Online

$9.27

0.32 (3.58%)

, MU

Micron

$59.06

-0.38 (-0.64%)

10:21
06/22/18
06/22
10:21
06/22/18
10:21
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

STG

Sunlands Online

$9.27

0.32 (3.58%)

MU

Micron

$59.06

-0.38 (-0.64%)

IDXG

Interpace Diagnostics

$0.90

0.0262 (3.00%)

AYX

Alteryx

$37.60

-1.03 (-2.67%)

BCRX

BioCryst

$5.55

-0.225 (-3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 10

    Jul

  • 12

    Jul

NKE

Nike

$74.13

0.19 (0.26%)

, CAKE

Cheesecake Factory

$58.01

-1.86 (-3.11%)

10:21
06/22/18
06/22
10:21
06/22/18
10:21
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

NKE

Nike

$74.13

0.19 (0.26%)

CAKE

Cheesecake Factory

$58.01

-1.86 (-3.11%)

HZN

Horizon Global

$6.52

-0.74 (-10.19%)

BKNG

Booking Holdings

$2,108.13

-13.8 (-0.65%)

VRX

Valeant

$24.26

-0.46 (-1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 27

    Aug

URI

United Rentals

$158.72

5.56 (3.63%)

, DG

Dollar General

$99.78

1.09 (1.10%)

10:21
06/22/18
06/22
10:21
06/22/18
10:21
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

URI

United Rentals

$158.72

5.56 (3.63%)

DG

Dollar General

$99.78

1.09 (1.10%)

SO

Southern Company

$45.34

0.04 (0.09%)

ES

Eversource

$56.09

0.39 (0.70%)

DRI

Darden

$107.60

0.53 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

IO

ION Geophysical

$21.85

0.5 (2.34%)

, SLB

Schlumberger

$67.20

2.41 (3.72%)

10:21
06/22/18
06/22
10:21
06/22/18
10:21
Periodicals
Schlumberger wins high court patent ruling over ION Geophysical, Bloomberg says »

Ion Geophysical (IO)…

IO

ION Geophysical

$21.85

0.5 (2.34%)

SLB

Schlumberger

$67.20

2.41 (3.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 20

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.